[1].Siegel, R.L., K.D. Miller and A. Jemal, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): p. 7-30.
[2].Torre, L.A., et al., Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev, 2016. 25(1): p. 16-27.
[3].Dong, B., et al., The prognostic value of lncRNA SNHG1 in cancer patients: a meta-analysis. BMC Cancer, 2019. 19(1): p. 780.
[4].Mai, H., et al., Molecular pattern of lncRNAs in hepatocellular carcinoma. J Exp Clin Cancer Res, 2019. 38(1): p. 198.
[5].Xia, J., et al., Ion channels or aquaporins as novel molecular targets in gastric cancer. Mol Cancer, 2017. 16(1): p. 54.
[6].Zheng, W., et al., Multiple Functions and Mechanisms Underlying the Role of METTL3 in Human Cancers. Front Oncol, 2019. 9: p. 1403.
[7].Liu, Z.X., et al., Link Between m6A Modification and Cancers. Front Bioeng Biotechnol, 2018. 6: p. 89.
[8].Roundtree, I.A., et al., Dynamic RNA Modifications in Gene Expression Regulation. Cell, 2017. 169(7): p. 1187-1200.
[9].Sun, T., R. Wu and L. Ming, The role of m6A RNA methylation in cancer. Biomed Pharmacother, 2019. 112: p. 108613.
[10].Shi, H., et al., YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res, 2017. 27(3): p. 315-328.
[11].Roignant, J.Y. and M. Soller, m(6)A in mRNA: An Ancient Mechanism for Fine-Tuning Gene Expression. Trends Genet, 2017. 33(6): p. 380-390.
[12].Ma, S., et al., The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol, 2019. 12(1): p. 121.
[13].Pan, Y., et al., Multiple functions of m(6)A RNA methylation in cancer. J Hematol Oncol, 2018. 11(1): p. 48.
[14]. Chen, X.Y., J. Zhang and J.S. Zhu, The role of m(6)A RNA methylation in human cancer. Mol Cancer, 2019. 18(1): p. 103.
[15].Zaccara, S., R.J. Ries and S.R. Jaffrey, Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol, 2019. 20(10): p. 608-624.
[16].Zhao, W., et al., Epigenetic Regulation of m(6)A Modifications in Human Cancer. Mol Ther Nucleic Acids, 2020. 19: p. 405-412.
[17].Liu, T., et al., The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res, 2020. 48(7): p. 3816-3831.
[18].Liu, N., et al., N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature, 2015. 518(7540): p. 560-4.
[19].Han, J., et al., METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer, 2019. 18(1): p. 110.
[20]. Ke, S., et al., A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation. Genes Dev, 2015. 29(19): p. 2037-53.
[21].Lin, S., et al., The m 6 A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. Molecular Cell, 2016. 62(3): p. 335-345.
[22].Peng, W., et al., Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway. J Exp Clin Cancer Res, 2019. 38(1): p. 393.
[23].Lin, S., et al., METTL3 Promotes the Proliferation and Mobility of Gastric Cancer Cells. Open Med (Wars), 2019. 14: p. 25-31.
[24].Meng, Q.Z., et al., METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2. Eur Rev Med Pharmacol Sci, 2020. 24(8): p. 4328-4336.
[25].Chen, W.W., et al., Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA. Eur Rev Med Pharmacol Sci, 2020. 24(8): p. 4263-4270.
[26]. Hu, Y., et al., METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B. Eur J Pharmacol, 2020. 879: p. 173134.
[27].Bokar, J.A., et al., Characterization and partial purification of mRNA N6-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. J Biol Chem, 1994. 269(26): p. 17697-704.
[28].Dominissini, D., et al., Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature, 2012. 485(7397): p. 201-6.
[29].Liu, T., et al., Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer. J Cell Physiol, 2020. 235(1): p. 548-562.
[30].Yuan, Y., et al., The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J Cancer, 2020. 11(12): p. 3588-3595.
[31].Liang, S., et al., METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway. Oncol Lett, 2020. 19(4): p. 3197-3204.
[32].Parmar, M.K., V. Torri and L. Stewart, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 1998. 17(24): p. 2815-34.
[33].Higgins, J.P. and S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat Med, 2002. 21(11): p. 1539-58.
[34].Bowden, J., et al., Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol, 2011. 11: p. 41.
[35].Lo, C.K., D. Mertz and M. Loeb, Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol, 2014. 14: p. 45.
[36].Gu, X., et al., Prognostic value of miRNA-181a/b in colorectal cancer: a meta-analysis. Biomark Med, 2018. 12(3): p. 299-308.
[37].Whiting, P., et al., The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol, 2003. 3: p. 25.
[38].Begg, C.B. and M. Mazumdar, Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994. 50(4): p. 1088-101.
[39].Yue, B., et al., METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer, 2019. 18(1): p. 142.
[40].Yang, D.D., et al., METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway. Front Oncol, 2020. 10: p. 115.
[41].Wang, Q., et al., METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut, 2019.
[42].Hua, W., et al., METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol, 2018. 151(2): p. 356-365.
[43].Li, T., et al., METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer, 2019. 18(1): p. 112.
[44].Zhou, Y., et al., Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets. Cancer Manag Res, 2019. 11: p. 3921-3931.
[45].Lin, Y., et al., METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma. Cancer Med, 2020. 9(8): p. 2859-2867.
[46].Zhu, W., et al., Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A-dependent manner. J Cell Mol Med, 2020. 24(6): p. 3521-3533.
[47].Cui, X., et al., Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway. Cell Prolif, 2020. 53(3): p. e12768.
[48].Wang, K., et al., Progression of Thyroid Carcinoma Is Promoted by the m6A Methyltransferase METTL3 Through Regulating m(6)A Methylation on TCF1. Onco Targets Ther, 2020. 13: p. 1605-1612.
[49].Xiao, S., et al., The RNA N(6)-methyladenosine modification landscape of human fetal tissues. Nat Cell Biol, 2019. 21(5): p. 651-661.
[50].Zhao, X. and L. Cui, Development and validation of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma. Am J Cancer Res, 2019. 9(10): p. 2156-2169.
[51].Wang, T., et al., The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer, 2020. 19(1): p. 88.
[52].He, L., et al., Functions of N6-methyladenosine and its role in cancer. Mol Cancer, 2019. 18(1): p. 176.
[53].Bokar, J.A., et al., Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA, 1997. 3(11): p. 1233-47.
[54].Wei, W., B. Huo and X. Shi, miR-600 inhibits lung cancer via downregulating the expression of METTL3. Cancer Manag Res, 2019. 11: p. 1177-1187.
[55].Lin, S., et al., METTL3 Promotes the Proliferation and Mobility of Gastric Cancer Cells. Open Med (Wars), 2019. 14: p. 25-31.
[56].Zhang, C., et al., Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer. Cancer Med, 2019. 8(10): p. 4766-4781.
[57].Liu, J., et al., m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol, 2018. 20(9): p. 1074-1083.
[58].Ji, J.W., et al., Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway. Eur Rev Med Pharmacol Sci, 2020. 24(7): p. 3818-3828.
[59].Miao, W., et al., The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1. Biochem Biophys Res Commun, 2019. 516(3): p. 719-725.
[60].Liu, L., et al., m(6)A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma. Mol Cancer, 2019. 18(1): p. 188.
[61].Deng, R., et al., m(6)A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways. Onco Targets Ther, 2019. 12: p. 4391-4402.
[62].Chen, J., et al., m(6)A Regulates Neurogenesis and Neuronal Development by Modulating Histone Methyltransferase Ezh2. Genomics Proteomics Bioinformatics, 2019. 17(2): p. 154-168.
[63].Yuan, Y., et al., The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J Cancer, 2020. 11(12): p. 3588-3595.
[64].Zhao, W., et al., METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m(6)A Modification. Mol Ther Nucleic Acids, 2020. 20: p. 1-12.
[65].Lee, H., et al., Stage-specific requirement for Mettl3-dependent m(6)A mRNA methylation during haematopoietic stem cell differentiation. Nat Cell Biol, 2019. 21(6): p. 700-709.
[66].Cheng, M., et al., The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene, 2019. 38(19): p. 3667-3680.
[67].Ma, X.X., Z.G. Cao and S.L. Zhao, m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1. Eur Rev Med Pharmacol Sci, 2020. 24(7): p. 3565-3571.
[68].Li, X., et al., The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma. ONCOTARGET, 2017. 8(56): p. 96103-96116.
[69].Du M, et al., MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA. Biochem Biophys Res Commun, 2017. 482(4): p. 582-589.